DFTX (Definium Therapeutics, Inc. Common Shares)
Insider Trading Activity
Every open-market purchase and sale reported by DFTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Matthew T. Wiley | Chief Commercial Officer | A | — | — |
| 2026-08-12 | Brandi Roberts | Chief Financial Officer | A | — | — |
| 2026-08-12 | Mark Sullivan | Chief Legal Officer | A | — | — |
| 2026-08-12 | Robert Barrow | Chief Executive Officer | A | — | — |
| 2026-08-12 | Daniel Karlin | Chief Medical Officer | A | — | — |
| 2026-06-26 | Daniel Karlin | Chief Medical Officer | Sell | — | — |
| 2026-06-26 | Mark Sullivan | Chief Legal Officer | Sell | — | — |
| 2026-06-26 | Matthew T. Wiley | Chief Commercial Officer | Sell | — | — |
| 2026-06-26 | Robert Barrow | Chief Executive Officer | Sell | — | — |
| 2026-06-26 | Brandi Roberts | Chief Financial Officer | Sell | — | — |
| 2026-06-22 | Daniel Karlin | Chief Medical Officer | A | — | — |
| 2026-06-22 | Mark Sullivan | Chief Legal Officer | A | — | — |
| 2026-06-22 | Matthew T. Wiley | Chief Commercial Officer | A | — | — |
| 2026-06-22 | Brandi Roberts | Chief Financial Officer | A | — | — |
| 2026-06-22 | Robert Barrow | Chief Executive Officer | A | — | — |
| 2026-06-15 | Andreas Krebs | Director | A | — | — |
| 2026-06-15 | ROGER CRYSTAL | Director | A | — | — |
| 2026-06-15 | Carol A Vallone | Director | A | — | — |
| 2026-06-15 | Roger Adsett | Director | A | — | — |
| 2026-06-15 | Suzanne Louise Bruhn | Director | A | — | — |
| 2026-06-15 | DAVID W GRYSKA | Director | A | — | — |
| 2026-03-26 | Daniel Karlin | Chief Medical Officer | Sell | — | — |
| 2026-03-26 | Robert Barrow | Chief Executive Officer | Sell | — | — |
| 2026-03-26 | Mark Sullivan | Chief Legal Officer | Sell | — | — |
| 2026-02-05 | Brandi Roberts | Chief Financial Officer | A | — | — |
| 2026-02-05 | Robert Barrow | Chief Executive Officer | A | — | — |
| 2026-02-05 | Mark Sullivan | Chief Legal Officer | A | — | — |
| 2026-02-05 | Daniel Karlin | Chief Medical Officer | A | — | — |
| 2026-02-05 | Matthew T. Wiley | Chief Commercial Officer | A | — | — |
| 2026-01-29 | Roger Adsett | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 1,473,246 | — |
| — | Chief Medical Officer | 603,282 | — |
| — | Chief Legal Officer | 383,071 | — |
| — | Chief Financial Officer | 271,987 | — |
| — | Chief Commercial Officer | 237,133 | — |
| — | Director | 24,289 | — |
| — | Director | 24,289 | — |
| — | Director | 21,210 | — |
| — | Director | 19,900 | — |
| — | Director | 19,773 | — |
| — | Director | 3,555 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DFTX quote page; the site-wide leaderboard is on the insider transactions hub.